Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 2Head & Neck 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Turcot syndrome 1Pancreatic Neoplasms 1Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1

Interventions

Carboplatin 551Pemetrexed 404Cisplatin 401Paclitaxel 273Docetaxel 255Gemcitabine 218pembrolizumab 191Bevacizumab 190Erlotinib Hydrochloride 184Radiotherapy 181Etoposide 147durvalumab 140Nivolumab 134Drug Therapy 127osimertinib 107atezolizumab 92Gefitinib 74Radiosurgery 72anlotinib 69Vinorelbine 68tislelizumab 52Irinotecan 51Ipilimumab 50130-nm albumin-bound paclitaxel 50Taxes 48Surgical Procedures, Operative 46Cetuximab 46sintilimab 45Albumin-Bound Paclitaxel 45apatinib 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × danvatirsen × Thoracic × Clear all
NCT03334617 2025-10-27

HUDSON

AstraZeneca

Phase 2 Active not recruiting
528 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02983578 2025-05-06

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
39 enrolled
GastrointestinalThoracic

Turcot syndrome, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03794544 2022-02-24

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

MedImmune LLC

Phase 2 Completed
84 enrolled 17 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡